Abstract
The SARS-CoV-2 pandemic represents an unprecedented global crisis necessitating novel approaches for, amongst others, early detection of emerging variants relating to the evolution and spread of the virus. Recently, the detection of SARS-CoV-2 RNA in wastewater has emerged as a useful tool to monitor the prevalence of the virus in the community. Here, we propose a novel methodology, called lineagespot, for the detection of SARS-CoV-2 lineages in wastewater samples using next-generation sequencing. Our proposed method was tested and evaluated using NGS data produced by the sequencing of three wastewater samples from the municipality of Thessaloniki, Greece, covering three distinct time periods. The results showed a clear identification of trends in the presence of SARS-CoV-2 mutations in sewage data, and allowed for a robust inference between the variants evident through our approach and the variants observed in patients from the same area time periods. Lineagespot is an open-source tool, implemented in R, and is freely available on GitHub.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the "Greece vs Corona: Flagship Action to address the SARS-CoV-2 crisis. Epidemiological study in Greece through extensive testing for virus and antibody detection, viral genome sequencing and genetic analysis of patients" project, which is funded by the General Secretariat for Research and Innovation, under the Public Investments Program (PIP). Additionally, this work was supported by ELIXIR, the research infrastructure for life-science data.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The sequencing of coronavirus 2 (SARS-CoV-2) samples that is performed at CERTH, in the context of the National Flagship Action "Greece vs Corona" (https://greecevscorona.gr/), has been approved by the CERTH Research Ethics Panel (application date 29/09/2020, review date 19/10/2020) with Reference Number: ETH.COM-56. The members of the Ethical Committee of CERTH, were Athanasios Konstandopoulos (chairman, agk{at}certh.gr), Anagnostis Argiriou (member, argiriou{at}certh.gr), Georgia Aifantopoulou (member, gea{at}certh.gr), Olga Kammona (member, kammona{at}certh.gr), and Ioannis Kompatsiaris (member, ikom{at}iti.gr).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Fixed typo in author name; author order updated, resized margins for better clarity.
Data Availability
The implemented code that produces the results of this paper, starting from the VCF files, is available on the GitHub repository: https://github.com/BiodataAnalysisGroup/lineagespot.
The raw FASTQ files are available through Zenodo: https://zenodo.org/record/4564182
